Can These Obesity Drug Stocks Bounce Back in 2014?

It’s been a brutal 12 months for Arena and VIVUS, which respectively sell the obesity drugs Belviq and Qsymia. Can these two beaten-down stocks bounce back in 2014?

Feb 12, 2014 at 2:32PM

Here's some good news -- America isn't the most obese nation in the world. The bad news is that America still ranks second behind Mexico, according to a United Nations report last July. About 31.8% of American adults are still classified as obese, compared to 32.8% in Mexico.

At first glance, those ominous numbers hint at a blockbuster market for a new generation of obesity drugs, such as Arena's (NASDAQ:ARNA) Belviq and VIVUS' (NASDAQ:VVUS) Qsymia, the first new obesity drugs approved by the FDA in 13 years.

The FDA has been wary of obesity drugs since the Fen-Phen (fenfluramine/phentermine) disaster in the 1990s, when fenfluramine, an appetite suppressor, was implicated in heart valve disease, pulmonary hypertension, and cardiac fibrosis. Fenfluramine was withdrawn from the U.S. market in 1997.

Therefore, peak sales estimates were high when Arena (NASDAQ:ARNA) and Eisai (NASDAQOTH:ESALY) launched Belviq in June 2013, and VIVUS (NASDAQ:VVUS) launched Qsymia in September 2012. Analysts believed that both Belviq and Qsymia could eventually hit peak sales of $1.2 billion.

Lackluster or blockbuster?
How well did Belviq and Qsymia actually fare? This chart is worth a thousand words:

ARNA Chart

Source: YCharts.

Although Arena (NASDAQ:ARNA) has held up better than VIVUS (NASDAQ:VVUS) over the past 12 months, sales for both drugs simply weren't that impressive:



U.S. Launch Date

Sales Since U.S. Launch



June 2013

$3.0 million (31.5% of Eisai's sales)*



September 2012

$18.0 million

Source: Arena and VIVUS quarterly reports. *Eisai markets Belviq globally, except in South Korea, Taiwan, Australia, New Zealand, and Israel.

Arena (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) bulls share a similar thesis -- sales will eventually pick up thanks to free samples, positive word-of-mouth among physicians and patients, and stronger distribution partnerships with insurers and pharmacy benefits managers (PBMs).

The bears believe that analysts overestimated the demand for obesity drugs, and bad memories of Fen-Phen will keep doctors and patients away from the drug. Moreover, VIVUS' (NASDAQ:VVUS) well-publicized management problems -- swapping three CEOs in three months, the resignation of company President Peter Tam, and a proxy battle against a majority shareholder -- all severely undermined investor confidence.

The biggest problem that both drugs face is trust. If Arena (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS)  fail to convince doctors, patients, and insurers of the safety of Belviq and Qsymia, Wall Street's peak sales estimates could soon be revised downwards.

Positive catalysts on the horizon
I believe that Wall Street's blockbuster projections for Belviq and Qsymia are overly optimistic, but both stocks have positive catalysts on the horizon which could boost Arena (NASDAQ:ARNA) and VIVUS' (NASDAQ:VVUS) stock performance in 2014.

On January 14, VIVUS (NASDAQ:VVUS) announced a new partnership with health care insurer Aetna. The partnership will integrate VIVUS' (NASDAQ:VVUS) Qsymia into a pilot program to evaluate the benefits of prescription medication in weight loss. Aetna's program will be offered to self-insured plan sponsors, and participants will receive a membership to Aetna and CarePass' Lose It! weight loss assistance mobile app. This is VIVUS' (NASDAQ:VVUS) second attempt at reaching mobile users, following the launch of its mobile fitness app in March 2013 which doubled as an advertisement for Qsymia.

On February 10, Arena (NASDAQ:ARNA) and Eisai (NASDAQOTH:ESALY) announced a new agreement with PBM CVS Caremark (NYSE:CVS), which the companies claim could help Belviq reach over half of all Americans. CVS (NYSE:CVS) is the second-largest PBM in America after Express Scripts, and the second-largest retail pharmacy chain after Walgreens.

Shares of Arena (NASDAQ:ARNA) jumped more than 7% after the announcement. However, the impact of the CVS Caremark (NYSE:CVS) deal could be overrated, considering that VIVUS (NASDAQ:VVUS) also holds similar agreements with Express Scripts and its subsidiary Medco Health Solutions.

Why Arena could be a better longshot than VIVUS
Here are two more realistic positive catalysts for Arena (NASDAQ:ARNA) instead -- the eventual approval of Bel-Phen (a combination of Belviq and phentermine), stronger promotional efforts from Eisai (NASDAQOTH:ESALY), better insurance coverage, and its approval in additional countries.

Although Bel-Phen sounds uncomfortably similar to Fen-Phen, the FDA considers phentermine (also an appetite suppressant) safe. Eisai will conduct a 12-week study of Bel-Pen throughout the year, with results expected by the fourth fiscal quarter of 2014.

Meanwhile, Eisai (NASDAQOTH:ESALY) has doubled its global Belviq sales force to 400. Arena (NASDAQ:ARNA) expects insurance coverage to expand from 40% of cost to 50% by next month, resulting in cheaper prescriptions. Eisai (NASDAQOTH: ELASY) has also submitted the drug for approval in Brazil and Taiwan.

While these catalysts won't make Belviq a guaranteed blockbuster, Arena (NASDAQ:ARNA) is definitely on more solid ground than VIVUS (NASDAQ:VVUS), which lacks a large pharma marketing partner like Eisai (NASDAQOTH:ESALY).

The brutal fundamentals
Although Arena and VIVUS are both unprofitable, speculative stocks, we should still compare their fundamental health.




Cash and Equivalents


Operating Cash Flow




180.70 million


18.24 million




346.45 million


(180.29 million)







Source: Yahoo! Finance, February 12.

VIVUS (NASDAQ:VVUS) appears to be a fundamentally cheaper stock, primarily due to its steeper price decline, but Arena (NASDAQ:ARNA) is on much firmer fundamental ground -- it has a much lower debt-to-equity ratio and a positive operating cash flow.

The Foolish takeaway
In closing, both Arena (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) remain risky bets for 2014, but Arena (NASDAQ:ARNA) remains a better choice than its conflict-ridden, financially unstable rival. Arena's (NASDAQ:ARNA) new partnership with CVS (NYSE:CVS), stronger marketing efforts, and possible new approvals for additional indications and countries could all help the company recover this year.

The Motley Fool's top stock for 2014...
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information